Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) PDMR dealings New York/London, 1 May 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative...
News Media & Publications
Update on IND Application for Oral Formulation of Foralumab for Treatment of NASH
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS...
PDMR dealings
Tiziana Life Sciences plc (Incorporated in England and Wales with company number 09665181) New York/London, 25 April 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative...
Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Trial with milciclib in Advanced Liver Cancer Patients
Tiziana Reports encouraging interim clinical data from an ongoing Phase 2a Clinical Trial with Milciclib in Patients with advanced liver cancer 80% of patients who completed treatment within the trial’s timeframe requested to continue treatment on compassionate use...
TR-1 – Notification of Major Holdings
TR-1 – Notification of Major Holdings New York/London, 15 April 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today...
Tiziana announces financial results for year ending 31 December 2018
Tiziana Life Sciences PLC ("Tiziana" or the "Company") Financial Results for the Year Ended 31 December 2018 London, 4 April 2019 – Tiziana Life Sciences plc (AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology...
Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS...
Directorate Change
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Directorate Change New York/London, 7 February 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM:...
Exercise of Warrants & Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") Exercise of Warrants & Issue of Equity New York/London, 11 December 2018 - Tiziana Life Sciences plc...
Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)
New York/London, 3 December 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the...
Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc(“Tiziana” or the “Company”) Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human...
Tiziana Life Sciences plc Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq listed ADSs
London, 26 November 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company”), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that in...
Tiziana Announces Closing of Offering and Resulting Total Voting Rights
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT...
Tiziana Announces temporary reduction to exercise prices of outstanding warrants
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT...
Tiziana Announces Pricing of Offering and Warrant Conversion Raising in Aggregate £4.51 million of New Equity Capital, Approval to List on the Nasdaq Global Market and Loan Conversion Extinguishing £1.39 million of Debt
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT...
Equity Placing to raise US$1,500,000
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Tiziana Life Sciences plc ("Tiziana" or the "Company") London, October 26, 2018 - Tiziana Life Sciences plc (AIM: TILS), a UK biotechnology company that focuses...
Tiziana Announces Filing of an Amended Registration Statement with the SEC
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT...
Video: Eyeing phase II clinical trial in HCC patients with milciclib
Dr. Kunwar Shailubhai talks to Tip TV about Tiziana receiving approval to start Phase IIa trials to test its leading compound milciclib, a CDK inhibitor as a treatment for hepatocellular carcinoma (HCC).